Charles Baker - Regeneron Pharmaceuticals Independent Director

<div class='circular--portrait' style='background:#0D8ECF;color: white;font-size:4em;padding-top: 15px;;'>RE</div>
REGN -- USA Stock  

Earning Report: February 6, 2020  

  Director
Mr. Charles A. Baker, J.D., is no longer Independent Director of the Company effective June 8, 2018
Age: 84        
914 847-7000  www.regeneron.com
Baker retired as Chairman, President, and Chief Executive Officer of The Liposome Company, Inc., a biopharmaceutical company, a position he had held since December 1989. During his career, Mr. Baker served in a senior management capacity in various other pharmaceutical companies, including tenures as Group Vice President, Squibb Corporationrationrationration and President, Squibb International, and various senior executive positions at Abbott Laboratories and Pfizer Inc. From 1994 to 2013, Mr. Baker served as a member of the board of directors of Progenics Pharmaceuticals, Inc., a biopharmaceutical company. `

Charles Baker Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 23.16 % which means that it generated profit of $23.16 on every $100 spent on asset. This is very large. Similarly, it shows return on stockholders equity (ROE) of 31.86 % meaning that it created $31.86 on every $100 dollars invested by stockholders.
The company currently holds 738 M in liabilities with Debt to Equity (D/E) ratio of 7.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Regeneron Pharmaceuticals has Current Ratio of 3.95 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Linda RhodesZoetis
2017
Yuchun LeeVertex Pharmaceuticals Incorpor
2012
Laurie BrlasPerrigo Company Plc
2016
Kalpana MorpariaDr Reddys Laboratories Ltd
2007
Min TangOrigin Agritech Limited
2009
James KangOrigin Agritech Limited
2010
Shikha SharmaDr Reddys Laboratories Ltd
2019
Larry CordellOrigin Agritech Limited
2012
Jeffrey SmithPerrigo Company Plc
2017
Lloyd CarneyVertex Pharmaceuticals Incorpor
2019
Gregory NordenZoetis
2013
Bruce SachsVertex Pharmaceuticals Incorpor
2017
Donal OConnorPerrigo Company Plc
2014
Bharat DoshiDr Reddys Laboratories Ltd
2016
Ellen HoffingPerrigo Company Plc
2008
Gary CohenPerrigo Company Plc
2009
Ravi BhoothalingamDr Reddys Laboratories Ltd
2000
William YoungVertex Pharmaceuticals Incorpor
2014
Elaine UllianVertex Pharmaceuticals Incorpor
2011
Bruce CarterDr Reddys Laboratories Ltd
2008
J MoreauDr Reddys Laboratories Ltd
2007

Entity Summary

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in USA and is traded on BATS Exchange. It employs 7674 people.Regeneron Pharmaceuticals (REGN) is traded on BATS Exchange in USA and employs 7,674 people.

Regeneron Pharmaceuticals Leadership Team

Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
George Sing, Independent Director
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Stock Performance Indicators

Return On Equity31.86
Return On Asset23.16
Profit Margin35.37
Operating Margin32.16
Current Valuation38.97 B